Population genetics for target identification

Drug Discovery Today: Technologies

Volumn 1, Issue 1, 2004, Pages 69-74

  Healy, Daniel G ^a   Abou Sleiman, Patrick M ^a   Goldstein, David B ^b   Wood, Nicholas W ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DNA; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; NEW DRUG; RECEPTOR PROTEIN; TRANILAST;

BIOINFORMATICS; CASE CONTROL STUDY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DNA SEQUENCE; DRUG RESPONSE; DRUG TARGETING; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN GENOME PROJECT; HYPERBILIRUBINEMIA; HYPOTHESIS; INTERNET; ISCHEMIC HEART DISEASE; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; PHENOTYPE; POPULATION GENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 13344281988     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2004.08.012     Document Type: Review

References (27)

1. A.B. Singleton et al. α-Synuclein locus triplication causes Parkinson's disease Science 302 2003 841
2. M. Farrer et al. Alpha-synuclein gene haplotypes are associated with Parkinson's disease Hum. Mol. Genet. 10 2001 1847-1851
3. O. Chiba-Falek and R.L. Nussbaum Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system Hum. Mol. Genet. 10 2001 3101-3109
4. D. Botstein and N. Risch Discovering genotypes underlying human phenotypes: Past successes for mendelian disease, future approaches for complex disease Nat. Genet. 33 Suppl. 2003 228-237
5. M. Ronaghi Pyrosequencing sheds light on DNA sequencing Genome Res. 11 2001 3-11
6. L. Peltonen and V.A. McKusick Genomics and medicine. Dissecting human disease in the postgenomic era Science 291 2001 1224-1229
7. D.B. Goldstein et al. Genome scans and candidate gene approaches in the study of common diseases and variable drug responses Trends Genet. 19 2003 615-622
8. C.S. Carlson et al. Mapping complex disease loci in whole-genome association studies Nature 429 2004 446-452
9. D.B. Goldstein Islands of linkage disequilibrium Nat. Genet. 29 2001 109-111
10. S.B. Gabriel et al. The structure of haplotype blocks in the human genome Science 296 2002 2225-2229
11. M.E. Weale et al. Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: Implications for linkage-disequilibrium gene mapping Am. J. Hum. Genet. 73 2003 551-565
12. P. Sebastiani et al. Minimal haplotype tagging Proc. Natl. Acad. Sci. USA 100 2003 9900-9905
13. J. Couzin Human genome. HapMap launched with pledges of $100 million Science 298 2001 941-942
14. N. Risch and K. Merikangas The future of genetic studies of complex human diseases Science 273 1996 1516-1517
15. D.B. Goldstein et al. Pharmacogenetics goes genomic Nat. Rev. Genet. 4 2003 937-947
16. S. Purcell et al. Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits Bioinformatics 19 2003 149-150
17. J.A. Staessen et al. Essential hypertension Lancet 361 2003 1629-1641
18. B. Devlin et al. Genomic control: A new approach to genetic-based association studies Theor. Popul. Biol. 60 2001 155-166
19. D.F. Reich and D.B. Goldstein Detecting association in a case-control study while correcting for population stratification Genet. Epidemiol. 20 2001 4-16
20. K.J. Rothman and S. Greenland In (K.J. Rothman S. Greenland eds.) Modern Epidemiology 1998 Lippincott-Raven Philadelphia 79-92
21. The Million Women Study. (1999) Design and characteristics of the study population. Breast Cancer Res. 1, 73-80
22. A.F. Wright et al. Gene-environment interactions: The BioBank UK study Pharm. J. 2 2002 75-82
23. Al Hopkins and C.R. Groom The druggable genome Nat. Rev. Drug Discov. 1 2002 727-730
24. W.E. Evans Pharmacogenomics: Marshalling the human genome to individualise drug therapy Gut 52 Suppl. 2, ii 2003 10-18
25. T.J. Lynch et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129-2139
26. J.G. Paez et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497-1500
27. T.M. Danoff et al. A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia Pharmacogenom. J. 4 2004 49-53